Mouse anti Human CD14, conjugated with FITC

1. Immunocytochemical investigation of normal and chronic lymphocytic leukaemia lymphocytes reveals unexpectedly frequent reactivity with some myelomonocytic associated antibodies. Woessner S; Florensa L; Besses C; Vila RM; Galles C; Palou L; Sabrafen JS Leuk Res 1992;16(5):505-10 2. Effect of cytokines and lipopolysaccharide on CD14 antigen expression in human monocytes and macrophages. Landmann R; Ludwig C; Obrist R; Obrecht JP J Cell Biochem 1991 Dec;47(4):317-29 3. Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucemies (GEIL). Solary E; Casasnovas RO; Campos L; Bene MC; Faure G; Maingon P; Falkenrodt A. Leukemia 1992 May;6(5):393-9 4. In situ hybridization of interleukin-1 in CD14-positive cells in rheumatoid arthritis. Wood NC; Dickens E; Symons JA; Duff GW Clin Immunol Immunopathol 1992 Mar;62(3):295-300 5. Expression of CD54, CD58, CD14, and HLA-DR on macrophages and macrophage-derived accessory cells and their accessory capacity. Ocklind G; Friedrichs D; Peters JH Immunol Lett 1992 Feb 15;31(3):253-8 6. IL-4 decreases the expression of the monocyte differentiation marker CD14, paralleled by an increasing accessory potency. Ruppert J; Friedrichs D; Xu H; Peters JH Immunobiology 1991 Aug;182(5):449-64